Clinical Report: Updates in myasthenia gravis from J&J, Cartesian

The competitive field in myasthenia gravis continued to take shape this week as J&J and Cartesian each had readouts for clinical products that could challenge approved drugs in the market.

Nearly five months after Johnson & Johnson (NYSE:JNJ) said anti-FCRN antibody nipocalimab met the primary endpoint in the Phase III VIVACITY-MG3 study to treat generalized myasthenia gravis (gMG), the pharma presented data from the study showing a significant improvement in activity scores compared with placebo when given over standard-of-care therapy...